March 28, 2025 12:20 PM EDT

CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug

Anna Brown

News Reporter

Bristol Myers Squibb, BeiGene, AstraZeneca and Pfizer secured European backing for label expansions, and a French pharma got its first drug approval recommendation, in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug

Anna Brown

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

CHMP rec­om­mends sev­en la­bel ex­pan­sions and one new ap­proval, re­jects Lil­ly Alzheimer's drug

News Reporter

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug